Physician profile
Stephanie Moore
NPI 1578834396
$3,012.63
in general payments reported to CMS, 2019-2025
36 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 90% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $500 · 2023: $559 · 2024: $617 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,253.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $374.20 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.81 | 2024-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $220.44 | 2022-2024 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $193.92 | 2021-2024 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $166.33 | 2024-2025 | Velphoro, Velphoro |
| Alexion Pharmaceuticals, INC. | $157.57 | 2023-2024 | Ultomiris |
| Aurinia Pharma U.S., INC. | $153.83 | 2022-2025 | Lupkynis |
| Amgen INC. | $129.99 | 2021-2025 | Krystexxa, Tavneos |
| Xeris Pharmaceuticals, INC. | $121.83 | 2025 | Gvoke Hypopen |
| Ardelyx, INC. | $121.61 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $104.45 | 2022-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $100.42 | 2023-2025 | Tarpeyo |
| Inspire Medical Systems, INC. | $95.59 | 2023 | Inspire |
| Daiichi Sankyo INC. | $84.87 | 2021-2024 | Injectafer |
| Abbott Laboratories | $83.78 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $81.68 | 2022-2025 | Terlivaz |
| Otsuka America Pharmaceutical, INC. | $56.70 | 2022-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $45.16 | 2025 | |
| Genzyme Corporation | $32.00 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $30.07 | 2021 | |
| Horizon Therapeutics Plc | $28.34 | 2022 | |
| Scpharmaceuticals INC. | $27.26 | 2025 | |
| Emd Serono, INC. | $26.37 | 2024 | |
| Medline Industries LP | $26.02 | 2023 | |
| Hologic Sales and Service, LLC | $25.94 | 2024 | Novasure, Myosure Tissue Removal Device |
| Ultragenyx Pharmaceutical INC. | $22.58 | 2023 | |
| Taiho Oncology, INC. | $22.39 | 2021 | |
| Merck Sharp & Dohme LLC | $18.94 | 2021 | |
| Pharmacosmos Therapeutics INC. | $18.22 | 2022 | |
| Celgene Corporation | $17.15 | 2021 | |
| Clovis Oncology, INC. | $15.86 | 2021 | |
| Karyopharm Therapeutics INC. | $14.84 | 2021 | |
| Lilly USA, LLC | $14.03 | 2021 | |
| Seagen INC. | $12.84 | 2021 | |
| Pfizer INC. | $12.80 | 2022 | |
| Epizyme, INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.